Information Journal Paper
APA:
Copy. (2019). Phase 1 Safety And Immunogenicity Trial of Recombinant Lactococcus Lactis Expressing Human Papillomavirus Type 16 E6 Oncoprotein Vaccine. Molecular Therapy: Methods and Clinical Development, 15(-), 0-0. SID. https://sid.ir/paper/1045770/en
Vancouver:
Copy. Phase 1 Safety And Immunogenicity Trial of Recombinant Lactococcus Lactis Expressing Human Papillomavirus Type 16 E6 Oncoprotein Vaccine. Molecular Therapy: Methods and Clinical Development[Internet]. 2019;15(-):0-0. Available from: https://sid.ir/paper/1045770/en
IEEE:
Copy, “Phase 1 Safety And Immunogenicity Trial of Recombinant Lactococcus Lactis Expressing Human Papillomavirus Type 16 E6 Oncoprotein Vaccine,” Molecular Therapy: Methods and Clinical Development, vol. 15, no. -, pp. 0–0, 2019, [Online]. Available: https://sid.ir/paper/1045770/en